Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 6/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90024 | 1.00 | SCN4A (0.48) | SCN4ATACR1DPP4F2HPGD | |
| SCHEMBL19312226 | 1.00 | SCN4A (0.48) | SCN4ATACR1DPP4F2HPGD | |
| Hydrochloric Acid SCHEMBL7609765 | 0.98 | SCN4A (0.47) | SCN4ATACR1DPP4F2HPGD | |
| Hydrochloric Acid SCHEMBL15264355 | 0.98 | SCN4A (0.47) | SCN4ATACR1DPP4F2HPGD | |
| SCHEMBL791984 | 0.84 | SCN4A (0.61) | SCN4ATACR1 | |
| SCHEMBL57799 | 0.84 | SCN4A (0.61) | SCN4ATACR1 | |
| SCHEMBL1419721 | 0.84 | SCN4A (0.61) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL7757109 | 0.83 | SCN4A (0.59) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL56787 | 0.83 | SCN4A (0.59) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL22229209 | 0.83 | SCN4A (0.59) | SCN4ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| CN-107074887-B | Substituted dihydropyrrolopyrazoles | 宇部兴产株式会社 | 2020-12-22 | — | — | CN | disclosed |
| US-10131679-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| WO-2017188358-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| WO-2017188357-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR DOSING IN COMBINATION WITH OTHER PSORIASIS TREATMENT DRUG | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| WO-2017188369-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF ATOPIC DERMATITIS | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | QDPR, CYP2D6, DCLK3 | SCN4A 239/4885TACR1 1879/4885DPP4 57/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | SCN4A 1452/4885TACR1 140/4885DPP4 436/4885 |
| US-10131679-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, DCLK3 | SCN4A 239/4885TACR1 1879/4885DPP4 57/4885 |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, KCNJ11 | SCN4A 228/4885TACR1 2050/4885DPP4 46/4885 |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | SCN4A 3765/4885TACR1 252/4885DPP4 562/4885 |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | CYP3A5, CYP11B2, CNR2 | SCN4A 2074/4885TACR1 207/4885DPP4 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.